Literature DB >> 18043510

VEGF attenuates hyperoxic injury through decreased apoptosis in explanted rat embryonic lung.

Americo E Esquibies1, Alia Bazzy-Asaad, Farshid Ghassemi, Hitoshi Nishio, Anil Karihaloo, Lloyd G Cantley.   

Abstract

Ambient oxygen concentration and vascular endothelial growth factor (VEGF)-A are vital in lung development. Since hypoxia stimulates VEGF-A production and hyperoxia reduces it, we hypothesized that VEGF-A down-regulation by exposure of airways to hyperoxia may result in abnormal lung development. An established model of in vitro rat lung development was used to examine the effects of hyperoxia on embryonic lung morphogenesis and VEGF-A expression. Under physiologic conditions, lung explant growth and branching is similar to that seen in vivo. However, in hyperoxia (50% O2) the number of terminal buds and branch length was significantly reduced after 4 d of culture. This effect correlated with a significant increase in cellular apoptosis and decrease in proliferation compared with culture under physiologic conditions. mRNA for Vegf164 and Vegf188 was reduced during hyperoxia and addition of VEGF165, but not VEGF121, to explants grown in 50% O2 resulted in partial reversal of the decrease in lung branching, correlating with a decrease in cell apoptosis. Thus, hyperoxia suppresses VEGF-A expression and inhibits airway growth and branching. The ability of exogenous VEGF165 to partially reverse apoptotic effects suggests this may be a potential approach for the prevention of hyperoxic injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18043510     DOI: 10.1203/PDR.0b013e31815b4857

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  The role of hypoxia and neurogenic genes (Mash-1 and Prox-1) in the developmental programming and maturation of pulmonary neuroendocrine cells in fetal mouse lung.

Authors:  Suzanne McGovern; Jie Pan; Guillermo Oliver; Ernest Cutz; Herman Yeger
Journal:  Lab Invest       Date:  2009-12-21       Impact factor: 5.662

2.  Pigment epithelium-derived factor mediates impaired lung vascular development in neonatal hyperoxia.

Authors:  Anne Chetty; Michelle Bennett; Linh Dang; Daisy Nakamura; Gong-Jie Cao; Sana Mujahid; MaryAnn Volpe; Ira Herman; S Patricia Becerra; Heber C Nielsen
Journal:  Am J Respir Cell Mol Biol       Date:  2015-03       Impact factor: 6.914

3.  Pulmonary epithelial neuropilin-1 deletion enhances development of cigarette smoke-induced emphysema.

Authors:  Anne Le; Rachel Zielinski; Chaoxia He; Michael T Crow; Shyam Biswal; Rubin M Tuder; Patrice M Becker
Journal:  Am J Respir Crit Care Med       Date:  2009-06-11       Impact factor: 21.405

4.  Effect of recombinant IL-10 on cultured fetal rat alveolar type II cells exposed to 65%-hyperoxia.

Authors:  Hyeon-Soo Lee; Chun-Ki Kim
Journal:  Respir Res       Date:  2011-05-24

Review 5.  Hyperoxia-induced bronchopulmonary dysplasia: better models for better therapies.

Authors:  Kiersten Giusto; Heather Wanczyk; Todd Jensen; Christine Finck
Journal:  Dis Model Mech       Date:  2021-02-23       Impact factor: 5.758

6.  Hmga2 is required for canonical WNT signaling during lung development.

Authors:  Indrabahadur Singh; Aditi Mehta; Adriana Contreras; Thomas Boettger; Gianni Carraro; Matthew Wheeler; Hector A Cabrera-Fuentes; Saverio Bellusci; Werner Seeger; Thomas Braun; Guillermo Barreto
Journal:  BMC Biol       Date:  2014-03-24       Impact factor: 7.431

7.  Heparin binding VEGF isoforms attenuate hyperoxic embryonic lung growth retardation via a FLK1-neuropilin-1-PKC dependent pathway.

Authors:  Americo E Esquibies; Anil Karihaloo; Susan E Quaggin; Alia Bazzy-Asaad; Lloyd G Cantley
Journal:  Respir Res       Date:  2014-03-19

8.  Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF).

Authors:  Shaney L Barratt; Thomas Blythe; Khadija Ourradi; Caroline Jarrett; Gavin I Welsh; David O Bates; Ann B Millar
Journal:  Respir Res       Date:  2018-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.